Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP926 in Juvenile Myoclonic Epilepsy
NCT07723963Phase 3Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in juvenile myoclonic epilepsy (JME) (3 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Change from baseline in myoclonic seizure days per 28 days at 16 weeks. Started Sep 2026; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
juvenile myoclonic epilepsy (JME)
Beyond the preview
Go deeper on NCT07723963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07723963.